Argus analyst Jasper Hellweg upgraded Mylan to Buy with a price target of $42, saying the stock appears to be close to an inflection after several quarters of underperformance. The analyst points to the company's Q3 earnings beat and its gross margin expansion of 280bps. Hellweg further cites Mylan's launch of a "record number of new generic and biosimilar products this year, significantly diversifying its portfolio" whereby no single product now accounts for more than 3% of revenue. The analyst also keeps his FY18 EPS view at $4.73 and nudges his FY19 outlook higher by 2c to $5.28 while noting the company's forward earnings multiple of 6.8-times, which is near the low end of its 5.8- to 16.3-times historical average.